EUVIMEDEUVIMED entdecken
Crossref

Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment

Scott Jerome, Mary Beth Farrell, Jaime Warren, Monica Embry-Dierson, Eric J Schockling

Journal of Nuclear Medicine Technology · 2023-06 · 51 (2) · 102-116

DOI: 10.2967/jnmt.123.265492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, online erschienen am 02.06.2023. Verfasst von Scott Jerome und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland School of Medicine, Westminster, Maryland. Hauptthemen laut MEDLINE: Cardiomyopathies, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac amyloidosis was thought to be rare, undiagnosable, and incurable. However, recently it has been discovered to be common, diagnosable, and treatable. This knowledge has led to a resurgence in nuclear imaging with 99mTc-pyrophosphate-a scan once believed to be extinct-to identify cardiac amyloidosis, particularly in patients with heart failure but preserved ejection fraction. The renewed interest in 99mTc-pyrophosphate imaging has compelled technologists and physicians to reacquaint themselves with the procedure. Although 99mTc-pyrophosphate imaging is relatively simple, interpretation and diagnostic accuracy require an in-depth knowledge of amyloidosis etiology, clinical manifestations, disease progression, and treatment. Diagnosing cardiac amyloidosis is complicated because typical signs and symptoms are nonspecific and usually attributed to other cardiac disorders. In addition, physicians must be able to differentiate between monoclonal immunoglobulin light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). Several clinical and noninvasive diagnostic imaging (echocardiography and cardiac MRI) red flags have been identified that suggest a patient may have cardiac amyloidosis. The intent of these red flags is to raise physician suspicion of cardiac amyloidosis and guide a series of steps (a diagnostic algorithm) for narrowing down and diagnosing the specific amyloid type. One element in the diagnostic algorithm is to identify monoclonal proteins indicative of AL. Monoclonal proteins are detected by serum or urine immunofixation electrophoresis and serum free light-chain assay. Another element is identifying and grading cardiac amyloid deposition using 99mTc-pyrophosphate imaging. When monoclonal proteins are present and the 99mTc-pyrophosphate scan is positive, the patient should be further evaluated for cardiac AL. The absence of monoclonal proteins and a positive 99mTc-pyrophosphate scan is diagnostic for cardiac ATTR. Patients with cardiac ATTR need to undergo genetic testing to differentiate between wild-type ATTR and variant ATTR. This article is the third in a 3-part series in this issue of the Journal of Nuclear Medicine Technology Part 1 reviewed amyloidosis etiology and outlined 99mTc-pyrophosphate study acquisition. Part 2 described 99mTc-pyrophosphate image quantification and protocol technical considerations. This article discusses scan interpretation along with cardiac amyloidosis diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesAmyloid Neuropathies, FamilialHumansDiphosphatesRadiopharmaceuticalsRadionuclide Imaging

Stichwörter der Autor:innen

99mTc-pyrophosphate imagingcardiac amyloidosisinterpretationquantificationtreatment

Substanzen

diphosphoric acidDiphosphatesRadiopharmaceuticals

Autor:innen und Institutionen

  • University of Maryland School of Medicine, Westminster, Maryland.
  • Intersocietal Accreditation Commission, Ellicott City, Maryland; marybethfarrell2016@gmail.com.
  • MedAxiom, Neptune Beach, Florida.
  • Noninvasive Cardiology, Norton Audubon Hospital, Louisville, Kentucky; and.
  • Outpatient Cardiovascular Diagnostics, Norton Healthcare, LLC, Louisville, Kentucky.

Zitieren

APA

Jerome, S., Farrell, M. B., Warren, J., Embry-Dierson, M., & Schockling, E. J. (2023). Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment. Journal of Nuclear Medicine Technology, 51(2), 102-116. https://doi.org/10.2967/jnmt.123.265492

Vancouver

Jerome S, Farrell MB, Warren J, Embry-Dierson M, Schockling EJ. Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment. Journal of Nuclear Medicine Technology. 2023;51(2):102-116. doi:10.2967/jnmt.123.265492

BibTeX
@article{Jerome2023,
  author = {Jerome, Scott and Farrell, Mary Beth and Warren, Jaime and Embry-Dierson, Monica and Schockling, Eric J},
  title = {Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment},
  journal = {Journal of Nuclear Medicine Technology},
  year = {2023},
  volume = {51},
  number = {2},
  pages = {102--116},
  doi = {10.2967/jnmt.123.265492}
}
Kostenlos starten →